The success of these experiments, and the demonstration of dystrophin transcript correction in human DMD muscle explants [15], suggests great promise for this approach as a therapy for DMD, with Phase I clinical trials recently underway. This evidence concerns the gene DMD and Duchenne muscular dystrophy.